CD151 expression marks atrial- and ventricular- differentiation from human induced pluripotent stem cells
-
- Nakanishi-Koakutsu, Misato
- Center for iPS Cell Research and Application, Kyoto University; Takeda-CiRA Joint program (T-CiRA); Division of Cardiology, Johns Hopkins University School of Medicine; Department of Surgery, Johns Hopkins School of Medicine
-
- Miki, Kenji
- Center for iPS Cell Research and Application, Kyoto University; Center for Organ Engineering, Department of Surgery, Massachusetts General Hospital; Department of Surgery, Harvard Medical School; Present address: Premium Research Institute for Human Metaverse Medicine, Osaka University
-
- Naka, Yuki
- Center for iPS Cell Research and Application, Kyoto University; Takeda-CiRA Joint program (T-CiRA)
-
- Sasaki, Masako
- Center for iPS Cell Research and Application, Kyoto University; Takeda-CiRA Joint program (T-CiRA)
-
- Wakimizu, Takayuki
- Center for iPS Cell Research and Application, Kyoto University; Takeda-CiRA Joint program (T-CiRA)
-
- Napier, Stephanie C.
- Takeda-CiRA Joint program (T-CiRA); Global Advanced Platform, Takeda Pharmaceutical Company Limited
-
- Okubo, Chikako
- Center for iPS Cell Research and Application, Kyoto University
-
- Narita, Megumi
- Center for iPS Cell Research and Application, Kyoto University
-
- Nishikawa, Misato
- Center for iPS Cell Research and Application, Kyoto University
-
- Hata, Reo
- Center for iPS Cell Research and Application, Kyoto University
-
- Chonabayashi, Kazuhisa
- Center for iPS Cell Research and Application, Kyoto University; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
-
- Hotta, Akitsu
- Center for iPS Cell Research and Application, Kyoto University; Takeda-CiRA Joint program (T-CiRA)
-
- Imahashi, Kenichi
- Takeda-CiRA Joint program (T-CiRA); Global Advanced Platform, Takeda Pharmaceutical Company Limited
-
- Nishimoto, Tomoyuki
- Takeda-CiRA Joint program (T-CiRA); Orizuru Therapeutics Incorporated
-
- Yoshida, Yoshinori
- Center for iPS Cell Research and Application, Kyoto University; Takeda-CiRA Joint program (T-CiRA)
Abstract
Current differentiation protocols for human induced pluripotent stem cells (hiPSCs) produce heterogeneous cardiomyocytes (CMs). Although chamber-specific CM selection using cell surface antigens enhances biomedical applications, a cell surface marker that accurately distinguishes between hiPSC-derived atrial CMs (ACMs) and ventricular CMs (VCMs) has not yet been identified. We have developed an approach for obtaining functional hiPSC-ACMs and -VCMs based on CD151 expression. For ACM differentiation, we found that ACMs are enriched in the CD151low population and that CD151 expression is correlated with the expression of Notch4 and its ligands. Furthermore, Notch signaling inhibition followed by selecting the CD151low population during atrial differentiation leads to the highly efficient generation of ACMs as evidenced by gene expression and electrophysiology. In contrast, for VCM differentiation, VCMs exhibiting a ventricular-related gene signature and uniform action potentials are enriched in the CD151high population. Our findings enable the production of high-quality ACMs and VCMs appropriate for hiPSC-derived chamber-specific disease models and other applications.
A novel strategy to efficiently differentiate into subtype-specific cardiomyocytes from human iPS cells. 京都大学プレスリリース. 2024-03-13.
Journal
-
- Communications Biology
-
Communications Biology 7 2024-02-28
Springer Nature
- Tweet
Details 詳細情報について
-
- CRID
- 1050017887577184640
-
- ISSN
- 23993642
-
- HANDLE
- 2433/287143
-
- Text Lang
- en
-
- Article Type
- journal article
-
- Data Source
-
- IRDB